News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN) Reverses $285 Million Charge as Cancer Trial Starts


9/4/2013 7:22:05 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AstraZeneca has reversed a previous pre-tax impairment charge of $285 million after launching a final-stage Phase III clinical trial for the experimental drug olaparib in ovarian cancer. The drug had earlier looked unlikely to get to market but confidence in its prospects has revived following more recent tests. AstraZeneca said on Wednesday that the reversal of the charge would be excluded from core earnings.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at RTT News
Read at News Release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES